Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Non-Contact laser could make glaucoma treatment easier

NCT ID NCT07408154

Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two FDA-approved laser treatments for open-angle glaucoma: the standard SLT and a newer, non-contact version called DSLT. Both aim to lower eye pressure and prevent vision loss. About 172 adults with glaucoma or high eye pressure will be randomly assigned to one treatment and followed for 12 months to see which is safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
laser treatment (Direct Selective Laser Trabeculoplasty or Selective Laser Trabeculoplasty)
What this could lead to
If DSLT works as well as or better than standard SLT, it could offer a more comfortable and efficient way to lower eye pressure and prevent vision loss in glaucoma patients.
What could go wrong
This is a relatively small, early-stage comparison. The newer DSLT may not prove superior or could have unexpected side effects. Results may not apply to all glaucoma types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 172 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Diagnosis of OAG (including exfoliative or pigmentary) or OHT * Gonioscopically open angle (visible scleral spur 360°) * Ability to consent and comply with follow-up Exclusion Criteria: * Angle-closure or secondary glaucomas * IOP \>35 mmHg despite therapy * Corneal pathology interfering with laser or IOP measurement * Recent ocular surgery (\<6 months) * Contraindications to study medications or procedures * Cognitive impairment preventing consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Exfoliative glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exfoliation syndrome glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ocular hypertension (OHT) Open-angle glaucoma (OAG)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • MUSC

    RECRUITING

    Charleston, South Carolina, 29407, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.